CA1023287A - Process for the preparation of carrier-bound proteins - Google Patents

Process for the preparation of carrier-bound proteins

Info

Publication number
CA1023287A
CA1023287A CA183,976A CA183976A CA1023287A CA 1023287 A CA1023287 A CA 1023287A CA 183976 A CA183976 A CA 183976A CA 1023287 A CA1023287 A CA 1023287A
Authority
CA
Canada
Prior art keywords
carrier
preparation
bound proteins
proteins
bound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA183,976A
Other languages
French (fr)
Other versions
CA183976S (en
Inventor
Dieter Jaworek
Karl-Heinz Botsch
Hans U. Bergmeyer
Klaus Beaucamp
Michael Nelbock-Hochstetter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Boehringer Mannheim GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2260185A external-priority patent/DE2260185C3/en
Application filed by Boehringer Mannheim GmbH filed Critical Boehringer Mannheim GmbH
Application granted granted Critical
Publication of CA1023287A publication Critical patent/CA1023287A/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/18—Multi-enzyme systems
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F289/00—Macromolecular compounds obtained by polymerising monomers on to macromolecular compounds not provided for in groups C08F251/00 - C08F287/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/06—Enzymes or microbial cells immobilised on or in an organic carrier attached to the carrier via a bridging agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
    • C12N11/082—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
    • C12N11/082—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • C12N11/087—Acrylic polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
    • C12N11/089—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
    • G01N33/545—Synthetic resin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/815—Carrier is a synthetic polymer
    • Y10S530/816—Attached to the carrier via a bridging agent
CA183,976A 1972-12-08 1973-10-23 Process for the preparation of carrier-bound proteins Expired CA1023287A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2260185A DE2260185C3 (en) 1971-06-09 1972-12-08 Carrier-bound protein and method for its production - US Pat

Publications (1)

Publication Number Publication Date
CA1023287A true CA1023287A (en) 1977-12-27

Family

ID=5863935

Family Applications (1)

Application Number Title Priority Date Filing Date
CA183,976A Expired CA1023287A (en) 1972-12-08 1973-10-23 Process for the preparation of carrier-bound proteins

Country Status (12)

Country Link
US (1) US3969287A (en)
JP (1) JPS5749197B2 (en)
BE (1) BE808354A (en)
CA (1) CA1023287A (en)
CH (1) CH619003A5 (en)
DK (1) DK141555C (en)
HU (1) HU169972B (en)
IL (1) IL43476A (en)
IT (1) IT1045912B (en)
SE (1) SE420498B (en)
SU (1) SU524521A3 (en)
ZA (1) ZA739318B (en)

Families Citing this family (255)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH593992A5 (en) * 1972-12-23 1977-12-30 Roehm Gmbh
GB1550819A (en) * 1975-06-04 1979-08-22 Nat Res Dev Polymeric support for biogically active materials
JPS5272284A (en) * 1975-12-12 1977-06-16 Dainippon Pharmaceutical Co Enzymeeimmunoassay reagent
US4108804A (en) * 1975-12-23 1978-08-22 Toru Seita Process for preparation of chromatography solid supports comprising a nucleic acid base-epoxy group containing porous gel
US4046723A (en) * 1976-04-22 1977-09-06 The Dow Chemical Company Azide bonding of a protein to a latex
US4179423A (en) * 1976-06-09 1979-12-18 Schenectady Chemicals, Inc. Water-soluble polyester imide resins
US4206261A (en) * 1976-06-09 1980-06-03 Schenectady Chemicals, Inc. Water-soluble polyester imide resin wire coating process
US4045384A (en) * 1976-07-23 1977-08-30 The Dow Chemical Company Method for forming an amide bond between a latex and protein
DE2708018A1 (en) * 1977-02-24 1978-09-07 Boehringer Mannheim Gmbh BIOLOGICALLY ACTIVE PROTEIN FIXED TO POLYAMIDE AND THE PROCESS FOR ITS PRODUCTION
EP0000938B1 (en) * 1977-08-22 1984-10-17 National Research Development Corporation Macromolecular covalent conjugates, methods for preparing and pharmaceutical compositions containing them
US4206286A (en) * 1977-11-14 1980-06-03 Technicon Instruments Corporation Immobilization of proteins on inorganic supports
US4338398A (en) * 1979-03-20 1982-07-06 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Immobilization of starch degrading enzymes
US4415665A (en) * 1980-12-12 1983-11-15 Pharmacia Fine Chemicals Ab Method of covalently binding biologically active organic substances to polymeric substances
DE3126551C2 (en) * 1981-07-04 1983-12-15 Rolf Dr. 8700 Würzburg Siegel Manufacturing process for materials for immobilizing proteins and carbohydrate groups
US4506019A (en) * 1982-09-24 1985-03-19 Leeco Diagnostics, Inc. Activated polymer container means and assay method employing the same
US4596777A (en) * 1983-08-10 1986-06-24 E. R. Squibb & Sons, Inc. Process for preparing (3S)-3-[[[2-(protected or unprotected amino)-4-thiazolyl]acetyl]amino]-2-oxo-1-azetidinesulfonic acid and 4-substituted derivatives thereof
US4609707A (en) * 1983-11-10 1986-09-02 Genetic Systems Corporation Synthesis of polymers containing integral antibodies
US4511478A (en) * 1983-11-10 1985-04-16 Genetic Systems Corporation Polymerizable compounds and methods for preparing synthetic polymers that integrally contain polypeptides
US4843010A (en) * 1983-11-10 1989-06-27 Genetic Systems Corporation Polymerization-induced separation immunoassays
US4711840A (en) * 1984-01-27 1987-12-08 Genetic Systems Corporation Polymerization-induced separation immunoassays
DE3486275T2 (en) * 1983-11-10 1994-09-08 Genetic Systems Corp Polymerizable compounds containing integral antibodies and their applications in immunoassays with separation induced by polymerization.
US4752638A (en) * 1983-11-10 1988-06-21 Genetic Systems Corporation Synthesis and use of polymers containing integral binding-pair members
JPH0820447B2 (en) * 1984-01-27 1996-03-04 ジェネティック システムズ コーポレーション Method for separating substances from liquid mixtures and immunoassay method
US4695624A (en) * 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4749647A (en) * 1984-06-22 1988-06-07 Genetic Systems Corporation Polymerization-induced separation assay using recognition pairs
ES2044933T3 (en) * 1986-08-07 1994-01-16 Minnesota Mining & Mfg EMULSIONS OF FLUORATED CHEMICAL PRODUCTS, BIOLOGICALLY ACTIVE AND STABLE.
US4808530A (en) * 1986-09-05 1989-02-28 The Ohio State University Protein immobilization by adsorption of a hydrophobic amidine protein derivative to a hydrophobic surface
US4885250A (en) * 1987-03-02 1989-12-05 E. I. Du Pont De Nemours And Company Enzyme immobilization and bioaffinity separations with perfluorocarbon polymer-based supports
US5063109A (en) * 1988-10-11 1991-11-05 Abbott Laboratories Covalent attachment of antibodies and antigens to solid phases using extended length heterobifunctional coupling agents
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
ES2084069T3 (en) * 1990-08-15 1996-05-01 Abbott Lab IMMUNO ASSAY REAGENTS AND METHOD FOR THE DETERMINATION OF CYCLOSPORINE.
US5612034A (en) * 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
US5482996A (en) * 1993-12-08 1996-01-09 University Of Pittsburgh Protein-containing polymers and a method of synthesis of protein-containing polymers in organic solvents
US5795865A (en) * 1994-01-11 1998-08-18 Dyax Corp. Kallikrein-inhibiting "kunitz domain" proteins and analogues thereof
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US6045797A (en) * 1994-03-14 2000-04-04 New York University Medical Center Treatment or diagnosis of diseases or conditions associated with a BLM domain
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US5708142A (en) 1994-05-27 1998-01-13 Genentech, Inc. Tumor necrosis factor receptor-associated factors
US5736624A (en) * 1994-12-02 1998-04-07 Abbott Laboratories Phosphatase activated crosslinking, conjugating and reducing agents; methods of using such agents; and reagents comprising phosphatase activated crosslinking and conjugating agents
US5837815A (en) * 1994-12-15 1998-11-17 Sugen, Inc. PYK2 related polypeptide products
US5837524A (en) * 1994-12-15 1998-11-17 Sugen, Inc. PYK2 related polynucleotide products
US5807989A (en) * 1994-12-23 1998-09-15 New York University Methods for treatment or diagnosis of diseases or disorders associated with an APB domain
US6300482B1 (en) 1995-01-03 2001-10-09 Max-Flanck-Gesellschaft Zuer For{Overscore (D)}Erung Der MDKI, a novel receptor tyrosine kinase
US6565842B1 (en) * 1995-06-07 2003-05-20 American Bioscience, Inc. Crosslinkable polypeptide compositions
US6020473A (en) * 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
US7005505B1 (en) 1995-08-25 2006-02-28 Genentech, Inc. Variants of vascular endothelial cell growth factor
EP0871729A1 (en) 1995-09-15 1998-10-21 Baylor College Of Medicine Steroid receptor coactivator compositions and methods of use
US6030945A (en) * 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
US6998116B1 (en) * 1996-01-09 2006-02-14 Genentech, Inc. Apo-2 ligand
US6046048A (en) * 1996-01-09 2000-04-04 Genetech, Inc. Apo-2 ligand
US20050089958A1 (en) * 1996-01-09 2005-04-28 Genentech, Inc. Apo-2 ligand
US20020165157A1 (en) * 1996-04-01 2002-11-07 Genentech, Inc. Apo-2LI and Apo-3 polypeptides
EP1500702A1 (en) * 1996-04-01 2005-01-26 Genentech, Inc. APO-2LI and APO-3 apoptosis polypeptides from the TNFR1 familiy
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
US6159462A (en) * 1996-08-16 2000-12-12 Genentech, Inc. Uses of Wnt polypeptides
US6462176B1 (en) 1996-09-23 2002-10-08 Genentech, Inc. Apo-3 polypeptide
WO1998033924A1 (en) 1997-01-31 1998-08-06 Genentech, Inc. O-fucosyltransferase
US20040241645A1 (en) * 1997-01-31 2004-12-02 Genentech, Inc. O-fucosyltransferase
US20020102706A1 (en) * 1997-06-18 2002-08-01 Genentech, Inc. Apo-2DcR
WO1999010484A1 (en) * 1997-08-26 1999-03-04 Genentech, Inc. Rtd receptor
DK0981618T4 (en) * 1997-05-15 2011-11-21 Genentech Inc Anti-Apo-2 antibody
US20100152426A1 (en) * 1997-05-15 2010-06-17 Ashkenazi Avi J Apo-2 receptor fusion proteins
US6342369B1 (en) * 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
EP1003856A1 (en) 1997-06-05 2000-05-31 Board of Regents, The University of Texas System Apaf-1, the ced-4 human homolog, an activator of caspase-3
AU740227B2 (en) * 1997-06-18 2001-11-01 Genentech Inc. Apo-2DcR
WO1999002192A1 (en) 1997-07-11 1999-01-21 Brandeis University Method of inducing apoptosis by reducing the level of thiamin
US20030175856A1 (en) * 1997-08-26 2003-09-18 Genetech, Inc. Rtd receptor
US20060141036A1 (en) * 1997-12-12 2006-06-29 Andrx Labs Llc HMG-CoA reductase inhibitor extended release formulation
DE69939732D1 (en) 1998-01-15 2008-11-27 Genentech Inc APO-2 LIGAND
PT1086138E (en) * 1998-06-12 2010-01-04 Genentech Inc Monoclonal antibodies, cross-reactive antibodies and method for producing the same
US6984719B1 (en) 1998-09-17 2006-01-10 Hospital Sainte-Justine Peptide antagonists of prostaglandin F2α receptor
US6368793B1 (en) * 1998-10-14 2002-04-09 Microgenomics, Inc. Metabolic selection methods
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
KR100719202B1 (en) 1998-10-23 2007-05-16 키린-암젠 인코포레이티드 A COMPOUND BINDING TO MPl RECEPTOR AND A PHARMACEUTICAL COMPOSITION THEREOF
US6982153B1 (en) 1998-12-03 2006-01-03 Targanta Therapeutics, Inc. DNA sequences from staphylococcus aureus bacteriophage 77 that encode anti-microbial polypeptides
US6861442B1 (en) 1998-12-30 2005-03-01 Sugen, Inc. PYK2 and inflammation
WO2000077179A2 (en) * 1999-06-16 2000-12-21 Icos Corporation Human poly(adp-ribose) polymerase 2 materials and methods
US20040235749A1 (en) * 1999-09-15 2004-11-25 Sylvain Chemtob G-protein coupled receptor antagonists
US20030138771A1 (en) * 1999-09-30 2003-07-24 Jerry Pelletier DNA sequences from S. pneumoniae bacteriophage DP1 that encode anti-microbal polypeptides
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
DE60025526T2 (en) 1999-11-16 2006-08-24 Genentech, Inc., South San Francisco ELISA FOR VEGF
DK1290013T3 (en) 2000-04-21 2006-06-26 Amgen Inc Apo-A1 / All-peptide derivatives
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
CA2416794A1 (en) * 2000-08-11 2002-02-21 Favrille, Inc. Method and composition for altering a t cell mediated pathology
US6911204B2 (en) * 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
BR0209546A (en) 2001-05-11 2004-06-29 Amgen Inc Composition of matter, DNA, expression vector, host cell, and methods for treating B-cell mediated autoimmune disease, lupus, B-cell mediated cancer, and B-cell lymphoma
EP2322229B1 (en) 2001-10-10 2016-12-21 Novo Nordisk A/S Remodeling and glycoconjugation of Factor IX
DK1578771T3 (en) 2001-10-10 2013-06-10 Novo Nordisk As Remodeling and glycoconjugation of peptides
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7332474B2 (en) * 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
US20040054082A1 (en) * 2001-12-03 2004-03-18 Bank David H Toughened polymer blends with improved surface properties
US20100311954A1 (en) * 2002-03-01 2010-12-09 Xencor, Inc. Optimized Proteins that Target Ep-CAM
EP2311432B1 (en) 2002-06-07 2014-12-24 Dyax Corporation Modified kunitz domain polypeptides and their use for reducing ischemia or the onset of a systemic inflammatory response associated with a surgical procedure
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
US7521530B2 (en) 2002-06-11 2009-04-21 Universite De Montreal Peptides and peptidomimetics useful for inhibiting the activity of prostaglandin F2α receptor
DK1542710T3 (en) 2002-08-28 2012-10-15 Dyax Corp Method of preserving organs and tissues
US6919426B2 (en) 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
SG155777A1 (en) 2003-04-09 2009-10-29 Neose Technologies Inc Glycopegylation methods and proteins/peptides produced by the methods
WO2005016348A1 (en) * 2003-08-14 2005-02-24 Icos Corporation Method of inhibiting immune responses stimulated by an endogenous factor
US20050054614A1 (en) * 2003-08-14 2005-03-10 Diacovo Thomas G. Methods of inhibiting leukocyte accumulation
US8399618B2 (en) 2004-10-21 2013-03-19 Xencor, Inc. Immunoglobulin insertions, deletions, and substitutions
US20060134105A1 (en) * 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
US8883147B2 (en) 2004-10-21 2014-11-11 Xencor, Inc. Immunoglobulins insertions, deletions, and substitutions
CA2540921A1 (en) * 2003-10-22 2005-09-01 Merz Pharma Gmbh & Co. Kgaa The use of 1-aminocyclohexane derivatives to modify deposition of fibrillogenic ass peptides in amyloidopathies
AU2005222384A1 (en) 2004-03-05 2005-09-22 Vegenics Limited Growth factor binding constructs materials and methods
CA2563334A1 (en) * 2004-04-16 2005-11-17 Genentech, Inc. Assay for antibodies
AU2005245875C1 (en) 2004-05-13 2017-08-31 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
JP2007538258A (en) * 2004-05-15 2007-12-27 ジェネンテック・インコーポレーテッド Cross-screening system and method for detecting molecules having binding affinity for a target molecule
JP2008500338A (en) * 2004-05-25 2008-01-10 イコス・コーポレイション Method for treating and / or preventing abnormal proliferation of hematopoietic cells
US8143380B2 (en) * 2004-07-08 2012-03-27 Amgen Inc. Therapeutic peptides
AU2005289685B2 (en) 2004-09-24 2009-07-16 Amgen Inc. Modified Fc molecules
US7235530B2 (en) * 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
DK2325207T3 (en) 2004-11-12 2017-06-06 Xencor Inc Fc variants with altered binding to FcRn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
AU2005318999B2 (en) 2004-12-22 2012-07-19 Genentech, Inc. Methods for producing soluble multi-membrane-spanning proteins
EP1885356A2 (en) * 2005-02-17 2008-02-13 Icos Corporation Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
WO2007008943A2 (en) 2005-07-08 2007-01-18 Xencor, Inc. Optimized anti-ep-cam antibodies
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
WO2007056411A2 (en) * 2005-11-08 2007-05-18 Genentech, Inc. Method of producing pan-specific antibodies
TW200736277A (en) 2005-11-14 2007-10-01 Amgen Inc RANKL antibody-PTH/PTHrP chimeric molecules
US7276480B1 (en) 2005-12-30 2007-10-02 Dyax Corp. Prevention and reduction of blood loss
US9012605B2 (en) 2006-01-23 2015-04-21 Amgen Inc. Crystalline polypeptides
JP2009529542A (en) * 2006-03-10 2009-08-20 ダイアックス コーポレーション Ecarantide formulation
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
US7981425B2 (en) 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
CA2654661C (en) 2006-06-26 2012-10-23 Amgen Inc. Compositions comprising modified lcat and use thereof for treating atherosclerosis
US8349801B2 (en) 2006-09-18 2013-01-08 Compugen Ltd. Peptide ligands for G-protein coupled receptors
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
WO2008060777A2 (en) 2006-10-04 2008-05-22 Genentech, Inc. Elisa for vegf
WO2008051383A2 (en) * 2006-10-19 2008-05-02 Amgen Inc. Use of alcohol co-solvents to improve pegylation reaction yields
US7803769B2 (en) * 2006-10-25 2010-09-28 Amgen Inc. OSK1 peptide analogs and pharmaceutical compositions
WO2008079322A1 (en) * 2006-12-22 2008-07-03 Beckman Coulter, Inc. Methods, kits and materials for diagnosing disease states by measuring isoforms or proforms of myeloperoxidase
WO2008153745A2 (en) 2007-05-22 2008-12-18 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
CA2693651A1 (en) 2007-07-12 2009-01-15 Ronen Shemesh Bioactive peptides and method of using same
EP2489730B1 (en) 2007-07-26 2015-12-30 Amgen, Inc Modified lecithin-cholesterol acyltransferase enzymes
US8715684B2 (en) 2007-08-28 2014-05-06 Ramot At Tel Aviv University Ltd. Peptides inducing a CD4i conformation in HIV gp120 while retaining vacant CD4 binding site
EP4098661A1 (en) 2007-12-26 2022-12-07 Xencor, Inc. Fc variants with altered binding to fcrn
WO2010027802A2 (en) * 2008-08-25 2010-03-11 New York University Methods for treating diabetic wounds
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
CN102271683B (en) 2008-11-13 2014-07-09 吉里德卡利斯托加公司 Therapies for hematologic malignancies
CA2744235A1 (en) * 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
EA019499B1 (en) 2009-03-24 2014-04-30 ГИЛИЭД КАЛИСТОГА ЭлЭлСи Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
EP2421536B1 (en) * 2009-04-20 2015-08-26 Gilead Calistoga LLC Methods of treatment for solid tumors
WO2011011550A1 (en) 2009-07-21 2011-01-27 Calistoga Pharmaceuticals Inc. Treatment of liver disorders with pi3k inhibitors
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
DK2494356T3 (en) * 2009-10-26 2017-05-15 Genentech Inc ASSAYS FOR THE DETECTION OF ANTIBODIES SPECIFIC TO THERAPEUTIC ANTI-IGE ANTIBODIES AND THEIR USE OF ANAPHYLAXY
AU2010316780B2 (en) 2009-11-05 2015-07-16 Rhizen Pharmaceuticals Sa Novel benzopyran kinase modulators
EP2521568B1 (en) 2010-01-06 2018-07-25 Dyax Corp. Plasma kallikrein binding proteins
US20110189178A1 (en) * 2010-02-04 2011-08-04 Xencor, Inc. Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions
WO2011097527A2 (en) 2010-02-04 2011-08-11 Xencor, Inc. Immunoprotection of therapeutic moieties using enhanced fc regions
EP2547359B1 (en) 2010-03-15 2016-03-09 The Board of Trustees of the University of Illionis Inhibitors of beta integrin-g protein alpha subunit binding interactions
EP3450432A1 (en) 2010-05-17 2019-03-06 Incozen Therapeutics Pvt. Ltd. Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued - 3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
US9254310B2 (en) 2010-06-17 2016-02-09 New York University Therapeutic and cosmetic uses and applications of calreticulin
WO2012030738A2 (en) 2010-08-30 2012-03-08 Beckman Coulter, Inc. Complex phosphoprotein activation profiles
WO2012045085A1 (en) 2010-10-01 2012-04-05 Oxford Biotherapeutics Ltd. Anti-rori antibodies
WO2012087943A2 (en) 2010-12-20 2012-06-28 The Regents Of The University Of Michigan Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
JOP20210044A1 (en) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co Anti-cd38 antibodies
IL310186A (en) 2011-01-06 2024-03-01 Takeda Pharmaceuticals Co Plasma kallikrein binding proteins
PE20140593A1 (en) 2011-03-16 2014-05-10 Amgen Inc POWERFUL AND SELECTIVE INHIBITORS OF NAV1.3 AND NAV1.7
BR112013027867A2 (en) 2011-04-29 2016-09-06 Bristol Myers Squibb Co "method of detecting the level of a sample anti-ip10 antibody, isolated monoclonal antibody or antigen binding portion thereof, hybridoma cell line and kit"
MY168757A (en) 2011-05-04 2018-12-04 Rhizen Pharmaceuticals S A Novel compounds as modulators of protein kinases
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
US8987422B2 (en) 2011-09-22 2015-03-24 Amgen Inc. CD27L antigen binding proteins
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
WO2013134288A1 (en) 2012-03-05 2013-09-12 Gilead Calistoga Llc Polymorphic forms of (s)-2-(1-(9h-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3h)-one
US20150079100A1 (en) 2012-03-23 2015-03-19 Bristol-Myers Squibb Company Methods of treatments using ctla-4 antibodies
JP2015518471A (en) 2012-03-28 2015-07-02 ジェネンテック， インコーポレイテッド Anti-HCMV idiotype antibodies and their use
US9815831B2 (en) 2012-03-30 2017-11-14 Rhizen Pharmaceuticals Sa 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of c-Met protein kinases
US10385395B2 (en) 2012-04-11 2019-08-20 The Regents Of The University Of California Diagnostic tools for response to 6-thiopurine therapy
UY34813A (en) 2012-05-18 2013-11-29 Amgen Inc ANTIGEN UNION PROTEINS DIRECTED AGAINST ST2 RECEIVER
TW201425336A (en) 2012-12-07 2014-07-01 Amgen Inc BCMA antigen binding proteins
EP2935311B1 (en) 2012-12-20 2021-03-31 Amgen Inc. Apj receptor agonists and uses thereof
WO2014114801A1 (en) 2013-01-25 2014-07-31 Amgen Inc. Antibodies targeting cdh19 for melanoma
JO3519B1 (en) 2013-01-25 2020-07-05 Amgen Inc Antibody constructs for CDH19 and CD3
AU2014214037A1 (en) 2013-02-06 2015-07-02 Pieris Ag Novel lipocalin-mutein assays for measuring hepcidin concentration
DK2956476T3 (en) 2013-02-18 2020-02-17 Vegenics Pty Ltd LANDAND-BINDING MOLECULES AND APPLICATIONS THEREOF
US10344060B2 (en) 2013-03-12 2019-07-09 Amgen Inc. Potent and selective inhibitors of Nav1.7
US9580486B2 (en) 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
KR102561553B1 (en) 2013-03-15 2023-07-31 젠코어 인코포레이티드 Heterodimeric proteins
CN110201144B (en) 2013-03-15 2024-01-02 得克萨斯州大学系统董事会 Inhibition of pulmonary fibrosis with Nutlin-3a and peptides
HUE045859T2 (en) 2013-03-15 2020-01-28 Amgen Res Munich Gmbh Single chain binding molecules comprising n-terminal abp
US10544187B2 (en) 2013-03-15 2020-01-28 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
US9260527B2 (en) 2013-03-15 2016-02-16 Sdix, Llc Anti-human CXCR4 antibodies and methods of making same
US9505849B2 (en) 2013-03-15 2016-11-29 Amgen Research (Munich) Gmbh Antibody constructs for influenza M2 and CD3
MX351127B (en) 2013-05-30 2017-10-03 Kiniksa Pharmaceuticals Ltd Oncostatin m receptor antigen binding proteins.
WO2015036956A1 (en) 2013-09-12 2015-03-19 Institut National De La Sante Et De La Recherche Medicale Method for in vitro quantifying allo-antibodies, auto-antibodies and/or therapeutic antibodies
SG11201601823TA (en) 2013-09-13 2016-04-28 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
AR097648A1 (en) 2013-09-13 2016-04-06 Amgen Inc COMBINATION OF EPIGENETIC FACTORS AND BIESPECTIVE COMPOUNDS THAT HAVE LIKE DIANA CD33 AND CD3 IN THE TREATMENT OF MYELOID LEUKEMIA
RU2016107435A (en) 2013-09-13 2017-10-18 Дженентек, Инк. COMPOSITIONS AND METHODS FOR DETECTING AND QUANTITATIVE DETERMINATION OF THE PROTEIN OF CELLS-OWNERS IN CELL LINES AND RECOMBINANT POLYPEPTIDE PRODUCTS
US10081682B2 (en) 2013-10-11 2018-09-25 Oxford Bio Therapeutics Ltd. Conjugated antibodies against LY75 for the treatment of cancer
ES2752552T3 (en) 2013-12-20 2020-04-06 Gilead Calistoga Llc Process methods for phosphatidylinositol 3-kinase inhibitors
WO2015095605A1 (en) 2013-12-20 2015-06-25 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (s) -2-(9h-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3h) -one
JP6691060B2 (en) 2014-01-17 2020-04-28 グリセリックス リミティド Cell surface prostate cancer antigen for diagnostics
KR102472816B1 (en) 2014-02-20 2022-11-30 알러간, 인코포레이티드 Complement component c5 antibodies
BR112016019825A2 (en) 2014-02-27 2017-10-17 Allergan Inc complement factor bb antibodies
AU2015235967B2 (en) 2014-03-27 2020-10-22 Takeda Pharmaceutical Company Limited Compositions and methods for treatment of diabetic macular edema
AU2015237184B2 (en) 2014-03-28 2020-11-26 Xencor, Inc. Bispecific antibodies that bind to CD38 and CD3
CA2951391C (en) 2014-06-10 2021-11-02 Amgen Inc. Apelin polypeptides
US11021467B2 (en) 2014-06-13 2021-06-01 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
TW201609812A (en) 2014-07-31 2016-03-16 安美基研究（慕尼黑）公司 Optimized cross-species specific bispecific single chain antibody constructs
AR101400A1 (en) 2014-07-31 2016-12-14 Amgen Res (Munich) Gmbh INDIVIDUAL CHAIN INDIVIDUAL CHAIN ANTIBODY CONSTRUCTION WITH IMPROVED FABRIC DISTRIBUTION
AR101669A1 (en) 2014-07-31 2017-01-04 Amgen Res (Munich) Gmbh ANTIBODY CONSTRUCTS FOR CDH19 AND CD3
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
MX2017011189A (en) 2015-03-06 2018-01-23 Genentech Inc Ultrapurified dsba and dsbc and methods of making and using the same.
WO2016149537A1 (en) 2015-03-17 2016-09-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bank vole prion protein as a broad-spectrum substrate for rt-quic-based detection and discrimination of prion strains
UA126270C2 (en) 2015-04-10 2022-09-14 Емджен Інк. Interleukin-2 muteins for the expansion of t-regulatory cells
CN116063541A (en) 2015-04-17 2023-05-05 安进研发（慕尼黑）股份有限公司 Bispecific antibody constructs for CDH3 and CD3
TWI717375B (en) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Antibody constructs for cd70 and cd3
TWI829617B (en) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Antibody constructs for flt3 and cd3
TWI796283B (en) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Antibody constructs for msln and cd3
TWI744242B (en) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Antibody constructs for egfrviii and cd3
TW202346349A (en) 2015-07-31 2023-12-01 德商安美基研究（慕尼黑）公司 Antibody constructs for dll3 and cd3
CN108026180B (en) 2015-08-28 2022-06-07 豪夫迈·罗氏有限公司 Anti-hypusine antibodies and uses thereof
BR112018011622A2 (en) 2015-12-11 2018-11-27 Dyax Corp method to treat hereditary angioedema attack (hae) or reduce hae attack rate
JOP20170017B1 (en) 2016-01-25 2021-08-17 Amgen Res Munich Gmbh Pharmaceutical composition comprising bispecific antibody constructs
DK3411402T3 (en) 2016-02-03 2022-02-07 Amgen Res Munich Gmbh BCMA AND CD3 BISPECIFIC T-CELL INVOLVING ANTIBODY CONSTRUCTIONS
EA039859B1 (en) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Bispecific antibody constructs binding egfrviii and cd3
WO2017134158A1 (en) 2016-02-03 2017-08-10 Amgen Research (Munich) Gmbh Psma and cd3 bispecific t cell engaging antibody constructs
JOP20170091B1 (en) 2016-04-19 2021-08-17 Amgen Res Munich Gmbh Administration of a bispecific construct binding to CD33 and CD3 for use in a method for the treatment of myeloid leukemia
JP7422480B2 (en) 2016-05-04 2024-01-26 アムジエン・インコーポレーテツド Interleukin-2 mutant protein for regulatory T cell proliferation
SG11201809642TA (en) 2016-05-16 2018-11-29 Baxalta Inc Anti-factor ix padua antibodies
CN117330747A (en) 2016-07-15 2024-01-02 武田药品工业株式会社 Methods and materials for assessing response to plasmacytoid and plasma cell depleting therapies
AU2018211064A1 (en) 2017-01-18 2019-09-05 Genentech, Inc. Idiotypic antibodies against anti-PD-L1 antibodies and uses thereof
JOP20190189A1 (en) 2017-02-02 2019-08-01 Amgen Res Munich Gmbh Low ph pharmaceutical composition comprising t cell engaging antibody constructs
GB201703876D0 (en) 2017-03-10 2017-04-26 Berlin-Chemie Ag Pharmaceutical combinations
UY37726A (en) 2017-05-05 2018-11-30 Amgen Inc PHARMACEUTICAL COMPOSITION THAT INCLUDES BISPECTIFIC ANTIBODY CONSTRUCTIONS FOR IMPROVED STORAGE AND ADMINISTRATION
WO2019075270A1 (en) 2017-10-12 2019-04-18 Amesino Llc Vegfr-antibody light chain fusion protein
EP3724229A1 (en) 2017-12-11 2020-10-21 Amgen Inc. Continuous manufacturing process for bispecific antibody products
UY38041A (en) 2017-12-29 2019-06-28 Amgen Inc CONSTRUCTION OF BIESPECFIC ANTIBODY DIRECTED TO MUC17 AND CD3
KR20210005097A (en) 2018-04-30 2021-01-13 메디뮨 리미티드 Conjugates that target and remove aggregates
GB201809746D0 (en) 2018-06-14 2018-08-01 Berlin Chemie Ag Pharmaceutical combinations
CN112584859A (en) 2018-07-02 2021-03-30 美国安进公司 anti-STEAP 1 antigen binding proteins
MX2021001221A (en) 2018-07-30 2021-06-23 Amgen Res Munich Gmbh Prolonged administration of a bispecific antibody construct binding to cd33 and cd3.
AU2019356564A1 (en) 2018-10-11 2021-04-29 Amgen Inc. Downstream processing of bispecific antibody constructs
WO2020081493A1 (en) 2018-10-16 2020-04-23 Molecular Templates, Inc. Pd-l1 binding proteins
AU2020290573A1 (en) 2019-06-13 2021-11-04 Amgen Inc. Automated biomass-based perfusion control in the manufacturing of biologics
CA3150441A1 (en) 2019-08-13 2021-02-18 Amgen Inc. Interleukin-2 muteins for the expansion of t-regulatory cells
MX2022002981A (en) 2019-09-10 2022-04-06 Amgen Inc Purification method for bispecific antigen-binding polypeptides with enhanced protein l capture dynamic binding capacity.
AU2020381536A1 (en) 2019-11-13 2022-04-21 Amgen Inc. Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
AU2020407208A1 (en) 2019-12-17 2022-06-02 Amgen Inc. Dual interleukin-2 /tnf receptor agonist for use in therapy
AU2021263767A1 (en) 2020-04-30 2022-09-08 Genentech, Inc. KRas specific antibodies and uses thereof
CA3183756A1 (en) 2020-05-19 2021-11-25 Amgen Inc. Mageb2 binding constructs
CA3183693A1 (en) 2020-05-29 2021-12-02 Amgen Inc. Adverse effects-mitigating administration of a bispecific construct binding to cd33 and cd3
BR112022024472A2 (en) 2020-06-01 2022-12-27 Genentech Inc METHODS FOR PRODUCING AN ANTIBODY, FOR DETECTING AN ANTIBODY IN A SAMPLE, FOR CLASSIFYING ANTIBODY-PRODUCING CELLS AND FOR PRODUCING A PLURALITY OF VESICLES, METHODS FOR PRODUCING AN ANTIBODY AND TREATMENT OF AN INDIVIDUAL WITH A DISEASE, ISOLATED ANTIBODIES, ISOLATED NUCLEIC ACID , HOST CELL, PHARMACEUTICAL COMPOSITION, USE OF ISOLATED ANTIBODY AND KIT
EP4169949A1 (en) 2020-06-23 2023-04-26 Jiangsu Kanion Pharmaceutical Co., Ltd. Anti-cd38 antibody and use thereof
WO2022013189A1 (en) 2020-07-14 2022-01-20 F. Hoffmann-La Roche Ag Assays for fixed dose combinations
CN116323671A (en) 2020-11-06 2023-06-23 安进公司 Multi-targeting bispecific antigen binding molecules with increased selectivity
JP2024513376A (en) 2021-04-02 2024-03-25 アムジエン・インコーポレーテツド MAGEB2 binding construct
IL307672A (en) 2021-05-06 2023-12-01 Amgen Res Munich Gmbh Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
CN113372514B (en) * 2021-06-22 2022-06-14 安徽农业大学 Preparation method of concanavalin polymer hydrogel, hydrogel prepared by preparation method and application of hydrogel
TW202346368A (en) 2022-05-12 2023-12-01 德商安美基研究（慕尼黑）公司 Multichain multitargeting bispecific antigen-binding molecules of increased selectivity
WO2024059675A2 (en) 2022-09-14 2024-03-21 Amgen Inc. Bispecific molecule stabilizing composition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3574062A (en) * 1967-04-20 1971-04-06 Beckman Instruments Inc Method of immobilizing enzymes and product
US3619371A (en) * 1967-07-03 1971-11-09 Nat Res Dev Production of a polymeric matrix having a biologically active substance bound thereto
SE343210B (en) * 1967-12-20 1972-03-06 Pharmacia Ab
FR1603393A (en) * 1967-12-27 1971-04-13
DE1908290C3 (en) * 1969-02-19 1982-04-08 Boehringer Mannheim Gmbh, 6800 Mannheim Acrylamide copolymer
GB1316990A (en) * 1970-09-17 1973-05-16 Roche Products Ltd Imidazolyl derivatives
AT317424B (en) * 1971-06-09 1974-08-26 Boehringer Mannheim Gmbh Process for the production of carrier-bound proteins

Also Published As

Publication number Publication date
HU169972B (en) 1977-03-28
IL43476A (en) 1976-03-31
DK141555C (en) 1980-09-22
JPS5749197B2 (en) 1982-10-20
JPS4986587A (en) 1974-08-19
IT1045912B (en) 1980-06-10
SE420498B (en) 1981-10-12
SU524521A3 (en) 1976-08-05
ZA739318B (en) 1974-11-27
BE808354A (en) 1974-06-07
US3969287A (en) 1976-07-13
CH619003A5 (en) 1980-08-29
DK141555B (en) 1980-04-21

Similar Documents

Publication Publication Date Title
CA1023287A (en) Process for the preparation of carrier-bound proteins
CA979449A (en) Process for the preparation of 1-hydroxy-2-pyridones
CA995682A (en) Process for the preparation of 3-cyanochromones
AU477038B2 (en) Process for the preparation of alpha-6-deoxytetracyclines
CA989868A (en) Process for the preparation of isopropylamines
AU474746B2 (en) Process for the preparation of thiazole-sulphenamides
AU472802B2 (en) Process for the preparation of 3-nitro-4-amino-toluene
AU471441B2 (en) Process for the preparation of 2-hydrazino-benzothiazoles
CA992967A (en) Process for the preparation of eburnamonines
CA1018182A (en) Process for the preparation of alkylene-bis-amides
CA1013763A (en) Process for the preparation of halomethylphosphinic acid halides
CA999867A (en) Process for the preparation of 2h-3-isoquinolones
CA1019097A (en) Process for the preparation of trans-polyalkenamers
CA1005058A (en) Process for the preparation of unsymmetrically-substituted alkanolamino-s-triazines
AU476031B2 (en) Process for the preparation of ketones
CA1006114A (en) Process for the preparation of chloroiminophosgene
CA996109A (en) Process for the preparation of 2-amino-benzylamines
CA972372A (en) Process for the preparation of aminoalkyleneindolines
CA905975A (en) Process for the preparation of acetoxy-3-phthalide
CA1006179A (en) Process for the preparation of chloroiminophosgene
CA914348A (en) Process for the preparation of trans-polypentenamers
CA915161A (en) Process for the preparation of 7-nitro-estratrienes
CA915706A (en) Process for the preparation of n-acyldopa
CA905935A (en) Process for the preparation of 19-norsteroids
CA904305A (en) Process for the preparation of quinoxaline-di-n-oxide-aldehyde